Standard Treatment Strategies and Precautions

Treating Autosomal Recessive Hypophosphatemic Rickets (ARHR) is a delicate balancing act. Because the body is constantly flushing out phosphate, treatment aims to replace just enough mineral to allow bones to harden without causing damage to the kidneys or blood vessels ^[1][2].

A Crucial Concept: In FGF23-mediated disorders, clinicians often do not try to normalize a single phosphate value, because normalizing phosphate with excessive dosing can be harmful ^[2]. Instead, targets are individualized, and treatment is balanced against parathyroid hormone (PTH), urinary calcium, alkaline phosphatase, symptoms, and bone radiographs. Never titrate doses yourself.

The Conventional Standard of Care

The conventional specialist-directed therapy for FGF23-mediated ARHR involves a combination of two medications: oral phosphate salts and active vitamin D (such as calcitriol or alfacalcidol) ^[1].

• Oral Phosphate Salts: These provide the raw material the bones are missing. However, because the kidneys continue to waste phosphate, this medication is typically taken in multiple doses throughout the day (often 3 to 5 times) to keep blood levels stable ^[2]. Missed doses should be discussed with your care team, and gastrointestinal side effects like diarrhea are common but can often be managed.
• Active Vitamin D (Calcitriol): High levels of FGF23 prevent the body from activating its own vitamin D. Taking calcitriol—the active form of the hormone—is used because it helps the intestines absorb the oral phosphate you are taking ^[3][2]. Without it, oral phosphate alone can cause severe parathyroid issues.

The Dosing Decision Tree

Treatment is not “one size fits all.” Doctors use a process called titration, where they start with a low dose and slowly adjust it based on several factors:

1. Clinical Response: Is bone pain improving? Is the child growing at a normal rate? ^[4]
2. Blood Work: Monitoring serum phosphate and Alkaline Phosphatase (a marker of bone health) ^[2].
3. Safety Monitoring: Checking urine for excess calcium (hypercalciuria) and the blood for Parathyroid Hormone (PTH) levels. If PTH climbs too high (secondary hyperparathyroidism), it can actually cause more phosphate to be lost ^[4][5].

Special Caution in ARHR2 (ENPP1)

If you or your child has ARHR2, the treatment strategy requires extra vigilance. In this subtype, the lack of pyrophosphate (a natural mineral-blocker) means the body is already prone to ectopic calcification—calcium hardening in the heart valves, arteries, or joints ^[6][7].

There is a theoretical concern that giving high doses of oral phosphate could worsen these calcifications by providing excess mineral that deposits in soft tissues ^[8][9]. While phosphate often improves the rickets (the bone softening), some small case reports have shown new or worsening calcifications in arteries or kidneys during treatment ^[10][11]. For this reason, many specialists advise careful, individualized dosing strategies and require cardiovascular monitoring ^[10]. Do not stop or reduce your prescribed therapy on your own out of fear of calcification; decisions must be individualized by an expert team.

The Role of Burosumab (Crysvita)

Burosumab is a newer, injectable therapy that directly blocks FGF23, stopping the phosphate wasting at its source.

• Approval Status: Currently, burosumab is officially approved for X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) ^[12][13]. Its use for ARHR is experimental and off-label.
• Use in ARHR1 (DMP1): Because ARHR1 and XLH share very similar biology, some doctors use burosumab “off-label” for ARHR1. Small case reports have described normalization of phosphate levels, healing of fractures, and reduced pain in a few patients ^[14][15].
• Caution in ARHR2 (ENPP1): There is currently much less evidence for using burosumab in ARHR2, and its safety remains unresolved. Because FGF23 might play a complex role in preventing calcification in ENPP1 deficiency, researchers are still studying whether blocking it is safe for these specific patients ^[8].

In approved uses, oral phosphate and active vitamin D analogues are generally not given concurrently with burosumab. Transitioning requires a supervised plan that discusses monitoring, insurance access, and the reality of unknown long-term safety in ARHR.